Original Research

Regional tenders on biosimilars in Italy: potentially competitive?

Published in: Volume 2 / Year 2013 / Issue 3
Author(s): , , , ,
Page: 123-9

Author byline as per print journal: Alessandro Curto, MSSc, Katelijne Van de Vooren, MSc, Roberta Lo Muto, MSc, Silvy Duranti, MBA, Professor Livio Garattini Introduction: Health care in Italy is… Read More »

Efficient production of recombinant parathyroid hormone (rPTH) fragment 1-34 in the methylotrophic yeast Hansenula polymorpha

Published in: Volume 2 / Year 2013 / Issue 3
Author(s): ,
Page: 114-22

Author byline as per print journal: Frank Mueller, MSc, Manal Moussa, MSc, Maria El Ghazaly, MSc, Jan Rohde, PhD, Nicole Bartsch, MSc, Antje Parthier, PhD, Frank Kensy, Dr Ing Background:… Read More »

How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria

Published in: Volume 2 / Year 2013 / Issue 2
Author(s): ,
Page: 65-75

Objective: To analyse similarities and differences between activities carried out by Austrian sickness funds to encourage more rational use of medicines, including increasing generics uptake. Methods: Semi-structured interviews with pharmacoeconomic… Read More »

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation

Published in: Volume 2 / Year 2013 / Issue 1
Author(s): , ,
Page: 13-9

Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself.… Read More »

Saving money in the European healthcare systems with biosimilars

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s): , , ,
Page: 120-6

Introduction: The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high… Read More »

European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution

Published in: Volume 9 / Year 2020 / Issue 3
Author(s): ,
Page: 116-24

Introduction: The European Union (EU) and the European Medicines Agency (EMA) have led the development of a regulatory framework for biosimilars since 2004. By end of December 2019, 64 biosimilars… Read More »

Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector

Author(s): ,

Introduction/Study Objectives: Etanercept is a tumor necrosis factor inhibitor indicated for the treatment of several inflammatory disorders. Patients with these diseases may experience manual dexterity challenges. Autoinjectors may improve dose… Read More »

Prices of cancer medicines across Europe; findings and implications for the future

Author(s): , ,

Introduction/Objectives: There are increasing concerns among health authorities regarding the sustainability of healthcare systems with growing expenditure on medicines driven by increasing use of biological medicines including new high-priced oncology… Read More »

Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching

Author(s): , , , , , , ,

Author byline as per print journal: Mansour Somaily1, MD; Hana Alahmari1, MD; Wejdan Abbag2; Shahenda Yousif4, MD; Nawar Tayfour4, MD; Nouf Almushayt2; Saleh Alhusayni3, MD; Saeed Almajadiah4, MD Background: A… Read More »

Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study

Published in: Volume 10 / Year 2021 / Issue 2

Author byline as per print journal: Pieter J Glerum1,2, MSc; Mert Hayta1,3, PharmD, MSc; David M Burger4, PharmD, PhD; Cees Neef5, PharmD, PhD; Marcel L Bouvy3, PharmD, PhD; Marc Maliepaard1,6,… Read More »

Page 5 of 5 « Previous1 2 3 4 5
Go Back Print